MannKind Corporation Reports 2018 Third Quarter Financial Results
November 01, 2018 08:00 ET
|
MannKind
Conference Call to Begin Today at 9:00 AM ET Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus royaltiesExecuted...
MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018
October 25, 2018 17:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host a conference call to discuss the 2018 third quarter and year-to-date financial results and...
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
October 16, 2018 06:00 ET
|
MannKind
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 (GLOBE NEWSWIRE) -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced...
Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity
October 15, 2018 09:00 ET
|
MannKind
Broadcast spot recognized at 2018 Medical Marketing & Media (MM&M) Awards WESTLAKE VILLAGE, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused...
MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes
October 04, 2018 09:00 ET
|
MannKind
Poster 813; PS 068 Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis ...
MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes
October 03, 2018 09:00 ET
|
MannKind
Presentation 55 Total and severe hypoglycemia is reduced with use of inhaled Technosphere® Insulin (TI) relative to insulin aspart in type 1 diabetes Poster 1046; PS 097 Diabetes duration, BMI, and...
MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients
September 24, 2018 09:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients...
Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics
September 13, 2018 09:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Sept. 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today that "Improved Postprandial Glucose with Inhaled Technosphere® Insulin Compared to...
United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products
September 04, 2018 06:00 ET
|
MannKind
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. and...
MannKind Corporation to Present at Upcoming Conferences
August 29, 2018 09:00 ET
|
MannKind
WESTLAKE VILLAGE, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for...